No profile data available.
Aligos Therapeutics, Inc. (ALGS) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in South San Francisco, United States, with about 82 full-time employees.
It reported revenue of $3.95 million for fiscal year 2024, down 74.6% from fiscal year 2023, and net income of -$131.21 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $741,000, down 41.6% from a year before. Its market capitalization was $33.35 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Aligos Therapeutics reported $3.95 million in revenue for fiscal year 2024, down 74.6% from $15.53 million in fiscal year 2023. In Q3 2025 revenue was $741,000.
$33.35 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Galectin Therapeutics Inc. (GALT), Enanta Pharmaceuticals, Inc. (ENTA), Precision BioSciences, Inc. (DTIL), Hepion Pharmaceuticals, Inc. (HEPA).